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Hemostatic defects are treated using coagulation factors; however, clot formation also
requires a procoagulant phospholipid (PL) surface. Here, we show that innate immune cell–
derived enzymatically oxidized phospholipids (eoxPL) termed hydroxyeicosatetraenoic
acid–phospholipids (HETE-PLs) restore hemostasis in human and murine conditions of
pathological bleeding. HETE-PLs abolished blood loss in murine hemophilia A and
enhanced coagulation in factor VIII- (FVIII-), FIX-, and FX-deficient human plasma . HETE-
PLs were decreased in platelets from patients after cardiopulmonary bypass (CPB). To
explore molecular mechanisms, the ability of eoxPL to stimulate individual isolated
coagulation factor/cofactor complexes was tested in vitro. Extrinsic tenase (FVIIa/tissue
factor [TF]), intrinsic tenase (FVIIIa/FIXa), and prothrombinase (FVa/FXa) all were enhanced
by both HETE-PEs and HETE-PCs, suggesting a common mechanism involving the fatty
acid moiety. In plasma, 9-, 15-, and 12-HETE-PLs were more effective than 5-, 11-, or 8-
HETE-PLs, indicating positional isomer specificity. Coagulation was enhanced at lower
lipid/factor ratios, consistent with a more concentrated area for protein binding. Surface
plasmon resonance confirmed binding of FII and FX to HETE-PEs. HETE-PEs increased
membrane curvature and thickness, but not surface charge or homogeneity, possibly
suggesting increased accessibility to cations/factors. In summary, innate immune-derived
eoxPL enhance calcium-dependent coagulation factor function, and their potential utility in
bleeding disorders is proposed.
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Introduction
Effective hemostasis requires multiple enzyme/cofactor complexes colocated on an electronegative phos-
pholipid (PL) membrane to first generate thrombin (factor IIa [FIIa]), which then cleaves fibrinogen to 
fibrin, forming a stable clot. Congenital factor deficiency or acquired hemostatic failure (associated with 
cardiac surgery) are routinely treated by coagulation factor replacement either individually or as fresh frozen 
plasma (FFP), while the potential role of  procoagulant PLs administered locally has not been considered.
Coagulation factor complexes are tissue factor (TF)/FVIIa (extrinsic tenase), FIXa/FVIIIa (intrinsic 
tenase), and FXa/FVa (prothrombinase), and they all require PL membranes to function (1–3). TF and 
PLs are also implicated in infection-associated coagulation (4–6). To support blood clotting, plasma mem-
branes externalize aminoPLs: phosphatidylserine (PS) and phosphatidylethanolamine (PE) (2, 3, 7, 8). PS 
is required to support coagulation, while PE enhances PS activity(9–11). PS and PE bind coagulation FII, 
FVII, FIX, and FX in a calcium-dependent manner, through their γ-carboxyglutamic acid (Gla) domains 
and FVIII and FV through homologous C domains(2, 12–14). Most studies on the interactions of  PLs 
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with coagulation factors have focused on head group involvement. However, PLs also differ with respect 
to the fatty acids (FA) at sn1 and sn2, with saturation and chain length differentially regulating coagulation 
in vitro (15, 16).
Activated platelets and innate immune cells rapidly generate enzymatically oxidized PLs (eoxPL), 
including variants of  PE and phosphatidylcholine (PC) by the action of  lipoxygenases (LOX)(15, 17–24). 
These lipids, some termed hydroxyeicosatetraenoic acid-PLs (HETE-PL) are localized at or near the mem-
brane surface, with 15-, 12-, and 5-HETE-PLs formed by macrophages/eosinophils, platelets, and neutro-
phils, respectively. Importantly, HETE-PLs were recently found to be an essential component of  normal 
hemostasis when formed in platelets or eosinophils (25, 26). These observations raised the possibility that 
eoxPLs could have a procoagulant effect in situations where hemostasis was impaired, and the mechanisms 
involved now require characterization.
To date, studies of  individual coagulation factor interactions with HETE-PLs have not been undertak-
en, and a full understanding of  how they act at a molecular level is lacking. Herein, we investigated their 
association with factors and their complexes, along with comparing PE and PC analogs and determining 
which HETE positional isomers best support thrombin generation in plasma. Biophysical parameters of  
HETE-PL–containing membranes were determined. To investigate their ability to affect hemostasis in sit-
uations of  impairment, we measured coagulation in plasma deficient in FVIII and in vivo in mice with 
hemophilia A. EoxPL endogenous levels and their ability to improve thrombin generation in plasma from 
patients at increased bleeding risk, due to a well-characterized depletion of  multiple factors was tested (27). 
Overall, we found that provision of  a procoagulant surface enables coagulation factors to work more effec-
tively in vitro and in vivo, compensating for a relative factor deficiency and improving defective hemostasis. 
Their ability to promote binding of  ions and positively charged proteins relates to improved steric access to 
PS. In summary, eoxPL facilitated enhanced coagulation factor activities on membrane surfaces. Further 
studies are required to establish whether these findings represent a potential new therapeutic strategy for 
acquired and genetic bleeding disorders.
Results
HETE-PLs enhance coagulation in FVIII-deficient plasma, acting in part through stimulating intrinsic tenase 
(FIXa/FVIIIa). To test the ability of  HETE-PLs to support coagulation in FVIII-deficient plasma (the 
situation with hemophilia A), we used liposomes with the following composition: HETE-PE lipo-
somes were 65% di-stearoyl-PC (DSPC), 30% 1-stearoyl-2-arachidonyl-PE (SAPE), and 5% 1-stea-
royl-2-arachidonyl-PS (SAPS), with SAPE replaced with <10% HETE-PE. HETE-PC liposomes 
were 55% DSPC, 10% 1-stearoly-2-arachidonyl-PC (SAPC), 30% SAPE, and 5% SAPS, with SAPC 
replaced with <10% HETE-PC. Thus, the only difference between control and HETE-PL liposomes 
was the HETE hydroxyl group. All were made in the presence of  10 pM recombinant human TF and 
used at 4 μM lipid concentration.
In FVIII-deficient plasma, 5-, 12-, or 15-HETE-PL liposomes supported a significant dose-dependent 
increase in thrombin generation (Figure 1). For 12- or 15-HETE-PLs, thrombin generation was restored to 
levels that were higher than HETE-PL–free control values obtained using healthy plasma (Figure 1, H, I, 
K, and L). This demonstrates that the lipids can overcome a clinically relevant factor deficiency to promote 
hemoastasis. Also, it shows that the procoagulant action of  HETE-PLs that we recently demonstrated in 
healthy plasma is at least partially dependent on FVIII (25). Although HETE-PLs enhanced thrombin 
generation in FVIII-deficient plasma, they were considerably more active in healthy plasma (seen as steeper 
slopes in concentration dose–response curves in Figure 1, G–L, for healthy vs. FVIII-deficient plasma). 
We note that different pooled plasma preparations contain different amounts of  coagulation factors and 
inhibitors; thus, HETE-PE–free controls are not identical between separate experiments. Within single 
experiments, the same platelet-poor plasma (PPP) preparation was always used for controls and samples 
containing HETE-PLs. HETE-PL also increases thrombin generation in the absence of  FIX (a model for 
hemophilia B) and FXI (Figure 2, A–D).
HETE-PL enhancement of  thrombin generation is increased by blocking TF pathway inhibitor, indicating 
that they stimulate extrinsic tenase/prothrombinase activities. To determine which factor complexes were 
stimulated by HETE-PL, we examined the effect of  blocking the TF pathway inhibitor (TFPI) using 
anti-TFPI. This allows TF/FVIIa to work at maximal rates and to directly cleave FX to FXa. In this 
condition, the activation through the extrinsic tenase (TF/FVIIa) is favored above the intrinsic tenase 
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(FVIIIa/FIXa). In normal and FVIII-deficient PPP, anti-TFPI enhanced thrombin generation in the 
absence of  HETE-PLs, as expected (Figure 2, E–L, and Figure 3, A and B). This is evidenced by control 
values in each representative trace being consistently higher in the presence of  anti-TFPI, and it is con-
sistent with higher activity of  TF/FVIIa, leading to direct cleavage of  FX to FXa. Inclusion of  5-, 12-, 
Figure 1. Hydroxyeicosatetraenoic acid–phospholipids (HETE-PLs) restore thrombin generation in FVIII-deficient plasma. Thrombin generation was mea-
sured using thrombinoscope as indicated in Methods using either healthy pooled or FVIII-deficient plasma. (A–F) Representative traces showing effect of 
HETE-PL positional isomers on thrombin generation in FVIII-deficient plasma. These were repeated 3 times to generate data shown in G–L. (G–L) Summary 
data showing the effect of dose dependence of HETE-PLs on coagulation (n = 3, mean ± SEM). Square, normal plasma; triangle, FVIII deficient plasma, **P < 
0.01, *P < 0.05 compared with no HETE-PL, as determined by 1-way ANOVA and post hoc Tukey tests.
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or 15-HETE-PL further increased thrombin generation in this situation (Figure 2, F, H, J, and L). For 
either healthy or FVIII-deficient plasma, similar thrombin generation rates were seen when TFPI was 
blocked (Figure 2, F, H, J, and L, and Figure 3, A and B). Notably, in this case, where intrinsic tenase is 
either lacking (FVIII deficiency) or relatively bypassed (anti-TFPI), thrombin generation enhancement 
by HETE-PL is equal, indicating that the lipids can act by stimulating extrinsic tenase (TF/FVIIa) and/
or prothrombinase (FVa/FXa).
Figure 2. HETE-PLs enhance thrombin generation in the absence of FIX or FXI, or in the absence of tissue factor pathway inhibitor (TFPI) and FVIII 
combined. (A and B) Thrombin generation was initiated by addition of liposomes to plasma deficient in FIX, as described in Methods. Liposomes were 
generated as described in Methods, and 10% 1-stearoyl-2-arachidonyl-PE (SAPE) was replaced with 10% 15-HETE-PE where indicated. (C and D) Thrombin 
generation was initiated by addition of liposomes to plasma deficient in FXI, as described in Methods. Liposomes were generated as described in Methods, 
and 10% SAPE was replaced with 10% 15-HETE-PE where indicated. (A–D) n = 3, mean ± SEM, *P < 0.05. A representative trace is shown for each. (E–H) 
Thrombin generation was initiated by direct addition of liposomes to plasma as described in Methods, at 10% HETE-PE, and measured in the absence (E 
and G) or presence (F and H) of 100 nmol/l anti-TFPI antibody preincubated for 15 minutes, in either normal (E and F) of FVIII-deficient plasma (G and H). 
(I–L) Thrombin generation was initiated by direct addition of liposomes to plasma as described in Methods, at 10% HETE-PC, and measured in the absence 
(I and K) or presence (J and L) of 80 nmol/l anti-TFPI antibody preincubated for 15 minutes, in either normal (I and J) of FVIII-deficient plasma (K and L). 
Data is shown as Tukey box plots, with 1-way ANOVA with Tukey post hoc multicomparison test. *P < 0.05.
5insight.jci.org   https://doi.org/10.1172/jci.insight.98459
R E S E A R C H  A R T I C L E
The fold-increase in peak thrombin observed with HETE-PLs in the presence of  anti-TFPI was less 
than in the absence of  anti-TFPI and was no longer dependent on FVIII (Figure 3, A and B). This is also 
consistent with a model in which HETE-PLs stimulate the activities of  all coagulation complexes in tandem.
HETE-PEs prevent bleeding in mice lacking FVIII. To extend our findings with FVIII-deficient human 
plasma to an in vivo model, we administered 12-HETE-PE (78 ng)/TF liposomes to FVIII-deficient mice, 
which are unable to stop bleeding following a tail cut. Strikingly, this resulted in an almost total restoration 
of  hemostasis in the FVIII-deficient mice, without any infusion of  exogenous FVIII and with blood loss 
less than that seen in mice with normal hemostasis treated with vehicle control liposomes (Figure 3, C and 
D). This provides proof-of-concept that provision of  a HETE-PL/TF surface represents a potential topical 
or locally administered treatment to reduce blood loss in situations where thrombin generation is impaired 
due to coagulation factor deficiency.
HETE-PLs stimulate activity of  TF/FVIIa, prothrombinase, and tenase complexes. To further determine the 
relative sensitivity of  individual enzyme/cofactor complexes to HETE-PLs, purified coagulation proteins 
were tested at physiological concentrations with eoxPL-containing liposomes. Extrinsic tenase (TF/FVIIa) 
activity was first determined by measuring cleavage of  FX to FXa. This was significantly increased by 
12-HETE-PE or 15-HETE-PE, but not by 12-HETE-PC (Figure 4, A and B). As control, HETE-PLs had 
no effect on cleavage of  the chromogenic substrate by FXa (data not shown). Similarly, all 3 HETE-PLs 
enhanced intrinsic tenase (FVIIIa/FIXa), with a lower effect for HETE-PC than -PEs (Figure 4, C and D). 
Last, 12- and 15-HETE-PE substantially increased thrombin generation by FXa/FVa (prothrombinase), 
while 12-HETE-PC was ineffective (Figure 4, E and F). Overall, HETE-PEs were more effective than PC 
analogs, with only HETE-PC significantly elevating intrinsic tenase activity. We note that enhancement of  
individual complexes is lower than the overall effect on the full cascade, as would be expected due to ampli-
fication effects of  multiple coagulation pathways working in tandem, as in plasma.
We next determined the effect of  HETE-PLs on Km
app and Vmax of  TF/FVIIa, FVIIIa/FIXa, and FVa/
FXa. These experiments use pico- or nanomolar concentrations of  enzymes and cofactors much lower than 
used for assays earlier, undertaken under physiological conditions. Surprisingly, significant differences were 
not observed using this approach (Supplemental Table 1; supplemental material available online with this 
Figure 3. HETE-PL restoration of hemostasis in mice lacking FVIII and enhancement of thrombin generation in FVIII deficiency, with/without tissue 
factor pathway inhibitor (TFPI) inhibition. (A and B) Summary data for thrombin generation in plasma as shown in Figure 3, E–L (n = 3, mean ± SEM). 
**P < 0.01, compared with control, as determined by 1-way ANOVA and post hoc Tukey tests. (C and D) 12-HETE-PE restores hemostasis in mice lacking 
FVIII. Male mice (11 weeks) were administered 78 ng HETE-PE in liposomes as described in Methods before a 3-mm tail cut. Bleeding time and Hb loss were 
determined as in Methods (n = 4–9 mice per group). Data is shown as Tukey box plots, with 1-way ANOVA with Tukey post hoc multicomparison test. *P < 
0.05, ***P < 0.005, data shown as squares in box plot are outliers (values 1.5–3 times lower or higher than the interquartile range).
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article; https://doi.org/10.1172/jci.insight.98459DS1). We hypothesized that this was due to the higher 
lipid/coagulation factor ratios used here. This was tested by measuring prothrombinase activity, varying 
lipid concentrations from 2–40 μM. Enhancement of  thrombin formation by HETE-PL was greater at low-
er lipid concentrations (Figure 4, G and H). These data show that HETE-PLs are more effective when PL 
is limited, most likely by enabling proteins to colocalize in smaller areas at higher concentrations, although 
further work is required to confirm this conclusion definitively. Limited availability of  aminophospholipids 
is expected to be the physiological situation when platelets are activated during hemostasis.
HETE-PLs reduce size of  liposomes and increase thickness of  the bilayer without significantly changing electro-
negativity, mobility, or size uniformity. We recently showed that HETE-PLs support enhanced PS-dependent 
binding of  calcium and the positively charged β2GP1 to membrane surfaces, suggesting they may increase 
electronegativity (25). To characterize the biophysics of  these liposomes, ζ potential (analogous to surface 
charge), electrophoretic mobility, polydispersity index (size uniformity), and diameter of  liposomes con-
taining varying 15-HETE-PE amounts were determined. The ζ potential of  PC-only liposomes became 
significantly more negative on incorporation of  physiological amounts of  native PE and PS, consistent 
with the hypothesis that aminoPLs enhance electronegativity of  cell membranes (Figure 5A). Inclusion of  
5% or 10% 15-HETE-PE, in place of  SAPE, caused no further increase (Figure 4A). Consistent with this, 
electrophoretic mobility of  the liposomes also decreased with PE/PS incorporation but did not further 
change with HETE-PE (Figure 5B). Liposome uniformity significantly improved (lower polydispersity) 
with PE/PS but was not further changed by HETE-PE (Figure 5C). In contrast, HETE-PE led to a signif-
icant decrease in liposome size (Figure 5D). Next, lamellar liquid crystalline lipid assemblies were exam-
ined to measure bilayer thickness in the presence of  15-HETE-PE. Small angle X-ray diffraction (SAXS) 
gives repeat spacing of  these structures, attributed to changes in bilayer thickness, although we note that it 
is measured under rather nonphysiological conditions, using lipid mesophases and at room temperatures; 
thus, it may not be fully representative of  a cellular lipid membrane. A significant increase in the lamellar 
repeat spacing from around 90 Å with 0%–2.5% 15-HETE-PE to around 105 Å with 5%–10% 15-HETE-
PE was seen, indicating membrane thickening (Figure 5E).
Overall, the data indicate that the inclusion of  aminoPL mediates major increases in electronegativity; 
however, HETE-PE liposomes are generally smaller (suggesting greater curvature), with a thicker bilayer. 
The lack of  increase in ζ potential indicates that locating the HETE –OH group near the membrane sur-
face, as we previously showed using molecular dynamics simulation, does not formally change surface 
charge (25). This suggests that HETE-PE may increase accessibility of  the phosphate to positively charged 
proteins/ions, possibly through reduction of  steric hindrance, promoting the ability of  membrane lipids to 
form H-bonds with ions/proteins. Whether these biophysical changes are associated with the enhancement 
of  coagulation reactions seen with HETE-PL requires further study.
Surface plasmon resonance demonstrates increased FII- and FX-binding to HETE-PE. Nanodiscs represent a 
potentially novel method for examining protein binding to lipid membranes. Unlike liposomes, they are flat, 
allowing an assessment of  the effect of  charge alone, without curvature. Using nanodiscs, the number of  FX 
or FII molecules binding to bilayers containing HETE-PE increased, although the effect was small (Figure 5, 
F–H). It is anticipated that the cumulative effect of  several coagulation factors associating with membranes 
at higher rates, and in the presence of  curvature, would lead to amplification of  coagulation in vivo.
HETE-PL positional isomers vary in their ability to enhance thrombin generation. Oxidation of  arachidonate to 
form HETEs can occur at 6 positions on the hydrocarbon backbone. To determine whether the position of  the 
–OH group conferred specificity, HETE-PL isomers were tested separately. All isomers enhanced thrombin 
Figure 4. HETE-PLs enhance extrinsic tenase (FVIIa/TF), intrinsic tenase (FVIIIa/FIXa), and prothrombinase (FVa/FXa) activities in vitro. (A and B) 
HETE-PLs enhance extrinsic tenase activity. Liposomes (4 mM) containing 50 pmol/l TF were added to FVIIa (10 nmol/l) and FX (136 nmol/l). Liposome 
composition for PE was 65% DSPC, 5% SAPS, 20% SAPE, with 10% SAPE (control) or 10% HETE-PE; for PC, it was 55% DSPC, 5% SAPS, 30% SAPE, 10% 
SAPC (control) or 10% HETE-PC. (A) Representative traces are shown from 1 of 4 experiments. (B) Summary data showing maximal thrombin generation  
(n = 4 separate experiments, each in triplicate, mean ± SEM). (C and D) HETE-PLs enhance intrinsic tenase activity. FVIIIa (300 pmol/l) was generated 
using FIIa and then inhibited by hirudin. This was added with substrate to FIXa (80 nmol/l), FX (136 nmol/l), and liposomes (without TF), and FXa gener-
ation was measured. (C) Representative traces from 1 of 3 experiments. (D) Summary data for maximal FXa generation (n = 3, mean ± SEM). (E–H) HETE-
PLs enhance prothrombinase activity. Liposomes (4 mM lipid, composition as above, with no TF) were added to FVa, FXa, and FII at 26 nmol/l, 136 nmol/l, 
and 1.4 μM respectively. (E and F) Representative data showing time courses for control and HETE-PL liposomes (n = 3 technical replicates, mean ± SEM). 
(G) Fold-changes at different lipid concentrations for HETE-PLs (differences between means, shown in H). (H) Prothrombinase activity in the presence of 
liposomes, at different lipid concentrations (n = 3–4, mean ± SEM) **P < 0.01, *P < 0.05, as determined by 1-way ANOVA and post hoc Tukey tests.
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Figure 5. HETE-PLs containing membranes directly bind Gla domain proteins, and specific HETE-PL positional isomers optimally support coag-
ulation. (A–C) Liposomes were analyzed using DLS for ζ potential, electrophoretic mobility, and polydispersity. Liposomes (65% DSPC, 5% DSPC, 
10%–0% SAPE, 0%–10% 15-HETE-PE) were analyzed using a Zetasizer Nano, as described in Methods (n = 3–5 separate liposome preparations, each 
analyzed as 4 replicates) and compared for differences against PC liposomes, using 1-way ANOVA with multicolumn comparison using Tukey. **P < 
0.01. (D) Liposomes (65% DSPC, 5% DSPC, 30%–0% SAPE, 0%–0% 15-HETE-PE) were analyzed by nanoparticle tracking analysis to determine the 
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generation in healthy plasma, with the magnitude varying but the pattern being the same for HETE-PE and 
PC (Figure 5, I–K). Thus, considering only enzymatically generated isomers, 12- and 15-HETE-PLs gener-
ated by activated platelets/murine macrophages and human monocytes/eosinophils, respectively, have the 
greatest effect on thrombin generation in plasma, with neutrophil 5-HETE-PL being less effective.
Generation of  HETE-PLs is reduced following cardiopulmonary bypass. We previously showed that HETE-
PEs externalize to the outside of  platelets following their generation, while HETE-PC is expected to be 
there already, since it is the predominant external facing PL in these cells (22). To investigate whether 
generation and externalization of  HETE-PLs as well as native PE and PS externalization is altered in 
a clinical situation associated with elevated bleeding risk and coagulation factor depletion (acquired), 
platelets were isolated from patients before cardiopulmonary bypass (CPB), at the time of  anesthesia, and 
immediately after CPB, following heparin reversal (the indications for surgery are given in Supplemental 
Table 2, n = 12). Platelets were activated using thrombin (0.2 IU/ml) or collagen (10 μg/ml); then, lipids 
were extracted and measured for 12-HETE-PLs and externalization of  total PE, PS, and 12-HETE-PE 
using (liquid chromatography-tandem mass spectrometry) LC/MS/MS. After CPB, platelets generated 
significantly less 12-HETE-PE (in response to thrombin) and externalized less 12-HETE-PE (in response 
to thrombin or collagen) or native PS (basal or in response to thrombin) (Figure 6, A–E). Trends toward 
lower levels and/or reduced externalization were evident for all lipids measured after CPB, either basally 
or after collagen/thrombin stimulation (Figure 6, A–E). These data suggest that, in addition to the recog-
nized platelet storage pool lesion that leads to reduced platelet aggregation (28), depressed activation of  
platelet LOX and/or scramblase activities may contribute to the elevated bleeding risk observed after CPB 
through suppressing generation of  the procoagulant surface required for effective hemostasis.
12-HETE-PL liposomes enhance thrombin generation more effectively in patients who did not require hemostatic 
treatment after CPB. Pre- and post-CPB plasma archived from 87 patients was tested for its ability to gen-
erate thrombin in the presence/absence of  HETE-PLs (Supplemental Table 3). The samples taken after 
CPB had significantly reduced coagulation factor levels and thrombin generation, as reported (27). Plas-
ma obtained before CPB was used with liposomes containing either native PL (5% SAPS, 30% SAPE, 
65% SAPC) or with 10% 12-HETE-PE or 12-HETE-PC in place of  SAPE. When measuring endogenous 
thrombin potential (ETP, total thrombin generated), peak thrombin activity, or velocity index (time to 
reach maximum thrombin), the fold increase in thrombin generation to HETE-PL liposomes was lower 
in patients who required FFP for clinically observed hemostatic impairment postoperatively (Figure 6, 
F–H). These data suggest that patients who develop clinical hemostatic impairment are overall less sen-
sitive to HETE-PLs, even before surgery. As platelets after CPB are also less able to generate a thrombo-
genic surface (Figure 6), this may further compromise thrombin generation and contribute to excessive 
bleeding. The mechanistic reasons for the difference in plasma responses to HETE-PLs between the 2 
patient groups before CPB remains to be explored.
HETE-PLs enhance thrombin generation in post-CPB plasma. Herein, we showed that HETE-PLs can 
improve thrombin generation in human plasma with FVIII deficiency (Figure 1). Similarly, we examined 
whether they enhance thrombin generation in post-CPB plasma. As expected, thrombin generation was 
significantly lower in plasma after CPB (vs. before CPB) (Figure 6I) due to reduced levels of  coagulation 
factors, as previously reported (27). However, thrombin generation was significantly increased by the inclu-
sion of  HETE-PLs, although the increase in post-CPB plasma appeared slightly lower. Along with our 
data using FVIII-deficient plasma and mice, this further supports the idea that eoxPL have the potential to 
improve coagulation in the context of  a bleeding defect due to reduced levels of  coagulation factors.
mean diameter (n = 4, mean ± SEM). (E) X-ray diffraction was carried out at beamline I22 (Diamond Light Source). Samples in glass capillary tubes 
were held at 37°C ± 0.1°C, and images were integrated as described in Methods (n = 3, mean ± SEM). (F–H) SPR analysis of protein binding to nano-
discs demonstrates increased binding in the presence of HETE-PE. Control discs were composed of 15% SAPS, 30% SAPE, and 55% DSPC. Nanodiscs 
containing HETE-PE were composed of 15% SAPS, 20% SAPE, 55% DSPC, and 10% HETE-PE. (F) Representative SPR-derived binding isotherms for 
FX binding to HETE-PE and control nanodiscs. Discs used were of the same composition as described for A. (G) Representative SPR-derived binding 
isotherms for prothrombin binding to HETE-PE containing and control nanodiscs. Discs used were of the same composition as described A. (H) Mole-
cules of protein bound per leaflet of nanodiscs in the presence or absence of HETE-PE. Summary data for experiments, n = 4 (FX), 2 (FII). (I–K) Posi-
tional isomer of HETE-PL influences potency of thrombin stimulation. Thrombin generation was initiated by addition of tissue factor containing lipo-
somes to plasma as described in Methods. (I) liposomes contained 65% DSPC, 5% SAPS, and 30% SAPE, with 10% SAPE replaced with 10% HETE-PE. 
(J) Liposomes contained 55% DSPC, 5% SAPS, and 30% SAPE, with 10% SAPC replaced with 10% HETE-PC. (K) Summary data for maximum thrombin 
generation (n = 3, mean ± SEM). ***P < 0.005, **P < 0.01, *P < 0.05, as determined by 1-way ANOVA and post hoc Tukey tests.
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Figure 6. Altered generation and action of HETE-PLs in a clinical setting of hemostatic failure associated with cardiopulmonary bypass surgery. (A–E) 
Platelets after CPB generate less HETE-PE and externalize less HETE-PE and PS than those isolated before CPB. Platelets isolated from peripheral blood 
of patients, before (shaded) and after (unshaded) CPB were measured for HETE-PE, HETE-PC, and externalized PE, PS, and HETE-PE basally and following 
thrombin or collagen activation, as described in Methods (n = 12). (F–H) Stimulation of thrombin generation in preoperative plasma by 12-HETE-PL was 
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Discussion
Human platelets, monocytes, neutrophils, and eosinophils acutely generate HETE-PLs via LOXs that 
remain cell associated, are elevated in thrombotic disease, and were recently shown to enhance hemosta-
sis in WT mice in vivo, although the mechanisms were not fully clarified (17–19, 21, 22, 24, 25, 29). We 
hypothesized that provision of  an enhanced procoagulant surface could represent a therapeutic opportuni-
ty in the context of  excess bleeding by partially compensating for coagulation factor deficiency. In studies 
designed to look for proof  of  principles of  this hypothesis, we show that coagulation can be enhanced in 
FVIII-, FIX-, and FXI-deficient human plasmas in vitro (Figures 1 and 2). In hemophilic mice in vivo, we 
showed that locally administered HETE-PL/TF liposomes prevented bleeding without the need for added 
FVIII (Figure 3). Furthermore, HETE-PE/TF liposomes corrected thrombin generation in post-CPB plas-
ma deficient in multiple coagulation factors (Figure 6).
Mechanistically, HETE-PL enhancement of  thrombin generation in FVIII-deficient or anti-TFPI–sup-
plemented plasma indicated that HETE-PLs can partially compensate for an absence of  FVIII and bypass 
the hemophilic defect. This may, in part, explain why people with hemophilia have variable bleeding phe-
notypes and thrombin generation in platelet-rich plasma, because platelets from different individuals will 
generate variable amounts of  HETE-PLs (30, 31). Hemophilic mice without FVIII bled excessively in a 
standard tail-clip model, as expected. Following local administration of  HETE-PE/TF containing lipo-
somes, bleeding was virtually eliminated, despite no FVIII replacement therapy being given. This suggests 
that, in some situations such as dental extraction or removal of  superficial skin lesions, local administra-
tion of  HETE-PE/TF containing liposomes could reduce the need for FVIII replacement. This hypothesis 
is untested and requires further study, and experiments in a relevant cutaneous wound model would be 
interesting (32). The finding that HETE-PLs also enhanced thrombin generation in the absence of  FIX or 
FXI suggests a role in hemophilia B and FXI deficiency. Bleeding after CPB is associated with significant 
coagulation depletion of  multiple coagulation factors (including FVIII), reduced thrombin generation, and 
an acquired platelet storage pool deficiency, which is known to impair platelet aggregation and adhesion 
(27, 33, 34). Herein, we showed that post-CPB platelets also had a reduced ability to externalize aminoPLs 
(native PS and PE) and generated reduced 12-HETE-PLs (Figure 6, F–H). This was associated with a 
decreased ability for these platelets to generate thrombin and could be an additional mechanism for hemo-
static impairment following CPB. Addition of  HETE-PL liposomes to plasma from patients obtained after 
CPB improved coagulation, despite multiple coagulation factor deficiencies, suggesting that these patients 
could be responsive to lipid-dependent coagulation stimulation strategies. This may explain, in part, why 
donor platelet transfusions, which can generate normal amounts of  HETE-PL, are often useful for arrest-
ing bleeding after CPB. Further studies are required to show whether these findings are reproducible, and 
the clinical implications of  the findings are, at present, speculative.
Separately, we found that pre-CPB plasma from patients who subsequently had clinical evidence of  
hemostatic impairment responded less well to the enhancing effects of  HETE-PLs, suggesting an inher-
ent difference in coagulation prior to surgery (Figure 6, F–H). The reasons for this remain unknown and 
require further investigation.
The procoagulant mechanism of  HETE-PLs may involve increased interaction of  coagulation factors 
and calcium at the platelet surface, as recently suggested (25). Herein, we tested which individual factors 
and enzyme complexes (FVa/FXa, FVIIIa/FIXa, and TF/FVIIa) are sensitive and, furthermore, which 
positional isomers of  HETE-PL are most effective. In isolation, all enzyme complexes were enhanced by 
HETE-PE; however, only intrinsic tenase was significantly enhanced by HETE-PC (Figure 3). In contrast, 
we found that, in plasma — where all factors act in concert — coagulation is slightly more sensitive to 
HETE-PC than -PE (Figure 5, I–K). It is possible that the action of  coagulation inhibitors such as anti-
thrombin, protein C, and TFPI in plasma may also be affected by HETE-PLs, but this has not been tested. 
significantly reduced in patients who received hemostatic treatment after CPB. Plasma from patients before CPB was added to 50 pmol/l TF liposomes 
with/without 10% HETE-PL, and thrombin was measured as described in Methods. ETP (F), peak thrombin (G), and velocity index (H) were determined and 
compared with responses to liposomes that contained native PL, to give fold changes for each. (I) Reduced thrombin generation seen in post-CPB plasma 
was restored using HETE-PL. Thrombin generation was compared in plasma before or after CPB using liposomes containing HETE-PL, as indicated (10%). 
For A–I, horizontal black lines represent median, boxes represent the interquartile range, bars represent values falling within 1.5 times the interquartile 
range, and asterisks/circles represent outliers (values 1.5–3 times lower or higher than the interquartile range). n = 87 for panels F–I. Data were analyzed 
using Wilcoxon rank test for paired variables, Mann Whitney U test for unpaired variables and Friedman’s 2-way analysis of variance with post hoc testing 
to compare repeated measures of related variables, **P < 0.01, *P < 0.05.
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Overall, our data using recombinant factors or human plasma (FVIII-deficient or with anti-TFPI) support 
the idea that HETE-PLs act to improve coagulation through stimulating several factor complexes in tan-
dem via a common mechanism, which is independent of  the headgroup and entirely dependent on the 
oxidized FA moiety.
FII, FVII, FIX, and FX contain Gla domains, specialized regions that contain posttranslational modi-
fications of  several glutamate residues by vitamin K–dependent carboxylation to form Gla. These mediate 
a high-affinity interaction of  calcium with negatively charged aminoPL on the cell surface, specifically PS 
and PE (11, 13). The cofactors FVIII and FV bind negatively charged PL via the homologous C1 and C2 
domains. Here, we found using nanodiscs that HETE-PLs improved Gla domain protein binding; however, 
potential additional interactions with cofactor C1/C2 domains may also occur in plasma and have not 
yet been explored. We note that the enhancement in plasma was greater than when testing recombinant 
factors, indicating that cooperativity between complexes occurs in plasma to orchestrate full blood clotting.
HETE-PL liposomes have a thicker bilayer and are slightly smaller, indicating greater curvature (Figure 
5, D and E). It is known that membrane curvature supports binding of  other charged proteins to mem-
branes, including amyloid-β, huntingtin, lactadherin, and Ras (35–38). However, since HETE-PE also 
enhances factor binding to flat nanodiscs, curvature alone doesn’t explain the effect (Figure 5, F–H). We 
have previously suggested that the polar –OH group causes the sn2 acyl chain to push headgroups apart, 
increasing interactions with phosphate groups (25). We also found that aminoPLs increase surface charge/
mobility, but no further elevation was seen with HETE-PE. This indicates that charge-dependent interac-
tions are increased by HETE-PL independently of  formally altering electronegativity. This is similar to 
the action of  PE, generally considered to support coagulation through enhancing interactions of  PS phos-
phates with positively charged ions/proteins, rather than through mediating direct factor binding or charge 
alterations itself. Whether these changes to membrane properties are linked to the enhanced coagulation 
reactions demonstrated with HETE-PL described herein is not known.
Enhancement of  factor activity was greatest at lower lipid concentrations, indicating that the total sur-
face area is a determinant; thus, enhancement by HETE-PLs is greater when available PL surface is limited 
(Figure 4, G and H). It is possible that a smaller surface area enables greater local concentration of  factors, 
enhancing interactions and activity rates, in concert with increased curvature. In support of  this idea, acti-
vated platelets were shown to concentrate annexin V and several factors and charged proteins at “ring” 
structures, suggesting that procoagulant/charged lipids localize in specialized areas at the cell surface — 
not across the whole platelet membrane (39–42). Whether this phenomenon is linked to the enhancement 
of  coagulation reactions described here requires further investigation.
We found that HETE-PLs differed in their ability to support thrombin generation depending on the posi-
tion of  oxidation. Of the enzymatically generated isomers, 5-HETE-PL — which is generated by neutrophils 
— had the weakest effect (Figure 5K). The –OH group on 5-HETE is located very close to the acyl carbonyl 
group and also to the PL phosphate. Thus, it will be already adjacent to the electronegative region of  the 
membrane, without any change in the localization of  the FA hydrocarbon chain being required. This is very 
different to other HETEs, where the –OH will be pushed further down into the nonpolar core when the FA 
is pointing downward. Thus, the impact of  the –OH on the orientation of  the FA is likely to be greater for all 
other HETEs than it would be for this positional isomer. This is a potential explanation for its relatively weak-
er effect and in line with our idea that the HETEs (except for this one) serve to push the headgroups apart in 
the membrane. This is, at this stage, a hypothesis.
In summary, we characterize the interactions of  endogenously generated eoxPL with individual fac-
tor complexes and show proof-of-principle studies for a potential clinical relevance in genetic/acquired 
bleeding disorders. The findings further our knowledge regarding how physiological membrane oxidation 
regulates innate immune cell function during acute activation/inflammation.
Methods
Materials. FVIII-, FIX-, and FXI-deficient plasmas were from Helena Biosciences UK. FII, FIIa, (human 
plasma–derived) FVII, FVIIa, FIX, FIXa, FX, FXa, and hirudin (recombinant),were from Enzyme 
Research Laboratories. FV and FVa (human plasma–derived), corn trypsin inhibitor (CTI, recombinant), 
and full-length TF (human recombinant) were from Haematologic Technologies Inc. FVIII (Advate, 
human full-length recombinant) was from Baxter Healthcare. FX chromogenic substrate S-2765 (N-a-Z-
D-Arg-Gly-Arg–para-nitro-aniline [pNA]) was from Quadratech Diagnostics. FIX chromogenic substrate 
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CS-51 (CH3SO2-D-CHG-Gly-Arg-pNA) was from Hyphen Biomed, FII chromogenic substrate Spectro-
zyme (H-D-HHT-Ala-Arg-pNA) was from Axis-Shield, and the FII fluorogenic substrate (Z-Gly-Gly-Arg-
AMC) was from Bachem. Anti–human-TFPI goat polyclonal antibody (catalog AF2974) was from R&D 
Systems. T-cal Thrombinoscope calibrator was from Stago. SAPE, SAPC, SAPS, and 1,2-DSPC were from 
Avanti Polar Lipids. MeOAVM (2,2’-Azobis[4-methoxy-2,4 dimethyl-valeronitrile]) was from WAKO. All 
other chemicals and lipsofast membranes were from MilliporeSigma, except N-methyl Benzohydroamic 
acid (NMBHA), synthesized in-house according to ref. 43. Solvents were from Thermo Fisher Scientific.
Synthesis of  HETE-PEs/PCs. HETE PE/PCs were synthesized as previously described, in a high-O2 
atmosphere (5–12 hours, 37°C) (44). SAPE (or SAPC; 0.2 M) was incubated with 0.3 M NMBHA and 
0.02 M MeOAMVN in chlorobenzene. When 50% of  the total lipid was oxidized, the lipid hydroperoxides 
were reduced using 2 moles equivalent of  triphenylphosphine, followed by stirring at 20°C for 1 hour. After 
drying, the sample was redissolved in ~1 ml acetonitrile and loaded onto 2 semi-preparative Discovery C18 
columns placed in a tandem sequence (5 mm pore). The sample was eluted isocratically using 5% MeOH in 
water, separating the 5-, 8-, 9-, 11-, 12-, and 15-HETE-PC/PEs, as detected by their absorbance at 235 nM 
and individually identified by MS. HETE-PE/PCs were stored at –80°C under inert gas.
Isolation of  plasma. Blood was taken into 0.32% sodium citrate and 0.59 U/ml CTI, final concentration 
20 μg/ml. Platelet rich plasma (PRP) was aspirated after a 10-minute spin at 460 g and then double-spun for 
10 minutes at 1,730 g to produce PPP. Pooled PPP was made from 4 healthy donors.
Generation of  liposomes. Liposomes were made by extrusion in 20 mmol/l HEPES, 100 mmol/l NaCl, 
pH 7.35 (buffer A). Where HETE-PE was substituted for unoxidized PE, the liposomes were 5% SAPS, 
20%–30% SAPE, 0%–10% HETE-PE, and 65% DSPC (mol%). Where unoxidized PC was substituted for 
HETE-PC, the liposomes were 5% SAPS, 30% SAPE, 55% DSPC, 0%–10% SAPC, and 0%–10% HETE-
PC. Liposomes were made in the presence of  10 pmol/l full-length recombinant TF and used at a final 
concentration of  4 μM total lipid unless otherwise stated (22).
Quantification of  blood loss from tail-bleeding assays. C57/BL6 WT (Charles River Laboratories) and 
FVIII-deficient mice were kept in constant temperature cages (20°C–22°C) and given free access to water 
and standard chow. Male mice (11 weeks old) were anesthetized using 5% isoflurane and maintained with 
2% isoflurane. Where administered, liposomes (10 μl generated as described above, using either [i] 30% 
SAPE, 65% DSPC, 5% SAPS, and 2.5 nM TF, or [ii] 20% SAPE, 65% DSPC, 5% SAPS, 10% 12-HETE-
PE, and 2.5 nM TF) were injected immediately distal of  the cut site and immediately before transec-
tion (total HETE-PE, 78 ng/dose). The tail was transected 3 mm from the distal end and immediately 
immersed in 37°C physiological saline. Bleeding was observed as blood loss, and time for stable cessation 
of  blood flow determined, before killing via cervical dislocation. Blood loss was quantified by measuring 
hemoglobin (Hb) content of  the saline as follows: Hb quantitation was achieved via centrifugation of  the 
tube at 250 g for 15 minutes, and resuspending RBCs in 5 ml erythrocyte lysis buffer (8.3 g/l NH4Cl, 1 
g/l KHCO3, and 0.037 g/l EDTA in distilled H2O). The concentration of  Hb was measured as OD 575 
nm using a UVIKON 923 double beam UV/VIS spectrophotometer (Bio-Tek Kontron Instruments) and 
expressed as absorbance units (AU).
Collection of  patient samples. Patients undergoing heart valve surgery with or without coronary artery 
bypass grafting and procedures on the aorta were recruited under a protocol approved by the South West 
Wales Research Ethics Committee (reference 11/WA/0215). Unfractionated heparin was used as antico-
agulant to maintain the activated clotting time (ACT) >400 seconds. Protamine at 1 mg per 100 units of  
heparin was given after CPB prior to removal of  the arterial and venous cannulae. Whole blood for prepa-
ration of  washed platelets or PPP was drawn from a central venous catheter after induction of  anesthesia 
(before CPB) and after CPB following reversal of  heparin. Heparin reversal was defined as ACT returning 
to within 10% of  baseline. ACT was measured using a Helena Actalyke MINI II (Helena Laboratories).
Patient information and inclusion and exclusion criteria for clinical studies. The median age was 70 years 
(interquartile range 59–78 years, range 33–88 years). Inclusion criteria included an age of  18 years or older, 
elective and urgent cardiac surgical procedures involving valve procedures, resternotomy operations on the 
aorta, and coronary artery bypass surgery combined with another procedure such as value replacement. 
Patients on warfarin were included after routine treatment to reverse international normalized ratio (INR), 
along with patients with any abnormality of  preoperative coagulation tests or liver impairment. Exclusion 
criteria were routine coronary artery bypass grafting as the sole procedure, administration of  antiplatelet 
agents other than aspirin within the last 5 days, a platelet count below 120 × 109/l, Hb less than 100 g/l, 
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or emergency procedures. Requirement for hemostatic therapy was defined as transfusion of  FFP after the 
reversal of  heparin. FFP was infused if  the clinicians managing the patient identified clinical evidence for 
hemostatic impairment. The laboratory investigators were not aware of  whether FFP had been infused 
until after assays had been completed.
Isolation of  human washed platelets in clinical studies. Washed platelets were prepared from whole blood 
drawn from a central venous catheter into syringes containing acidified citrate dextrose (ACD; 85 mM 
trisodium citrate, 65 mM citric acid, 100 mM glucose) at a ratio of  8.1 parts whole blood to 1.9 parts ACD, 
as described previously (32) and were resuspended in modified Tyrode’s buffer (134 mM NaCl, 12 mM 
NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1.0 mM MgCl2, 10 mM HEPES, 5 mM glucose, pH 7.4) at 
2 × 108/ml. Platelets (1.1 ml) were incubated at 37oC for 10 minutes with 1 mM CaCl2, 0.2 U/ml human 
thrombin (MilliporeSigma), 10 mg/ml collagen (Mascia-Brunelli), or modified Tyrode’s buffer.
Externalization of  platelet PL in platelets from patients. Biotinylated standards (DMPE-B, DMPS-B) were 
generated as described (45). For biotinylation of  total PE and PS, an 100-μl platelet sample was added to 20 
μl of  20 mM EZ-link NHS-Biotin (Thermo Fisher Scientific) dissolved in dimethyl sulfoxide (MilliporeSig-
ma). EZ-link sulfo-NHS-Biotin dissolved in modified Tyrode’s buffer at a concentration of  5 mg/ml and 
602 μl was added to the remainder of  the sample for biotinylation of  external PE and PS. Both samples 
were then incubated for 10 minutes at room temperature. Lysine was dissolved in modified Tyrode’s buffer 
at a concentration of  0.0366 g/ml, and 504 μl was then added to the platelet suspension to quench the 
reaction for a further 10 minutes. Internal standards were added: 10 ng DMPS-B, DMPE-B, DMPC, and 
DMPE. PLs were extracted using the method described by Bligh and Dyer (46). These were stored at –80oC 
before LC/MS/MS analysis. MS for biotinylated PE and PS was performed on a Q-Trap 4000 (AB Sciex 
UK Limited) as described previously (45).
Lipid extraction and LC/MS/MS of  oxidized lipids. Total HETE-PE/PCs were determined as described pre-
viously (47). Lipids were extracted using hexane/isopropanol/acetic acid as described below. 1,2-dimyris-
toyl-PE or -PC (10 ng) was added to each sample before extraction as an internal standard. Lipids were 
extracted by adding a solvent mixture (1 M acetic acid, 2-propanol, hexane [2:20:30]) to the sample at a ratio 
of  2.5 ml solvent mixture to 1 ml sample, vortexing, and then adding 2.5 ml of  hexane. Following vortexing 
and centrifugation (300 g, 5 minutes), lipids were recovered in the upper hexane layer. The samples were then 
reextracted by the addition of  an equal volume of  hexane followed by further vortexing and centrifugation. 
The combined hexane layers were then dried under a vacuum and analyzed for HETE-PE using LC/MS/
MS. Samples were separated on a Luna 3 μm C18 150 mm × 2 mm column (Phenomenex) gradient of  
50%–100% solvent B over 10 minutes, followed by 30 minutes at 100% B (Solvent A: methanol/acetonitrile/
water, 1 mM ammonium acetate, 60:20:20. Solvent B: methanol, 1 mM ammonium acetate) with a flow rate 
of  200 μl/min. Electrospray mass spectra were obtained on a Q-Trap instrument (Applied Biosystems 4000 
Q-Trap) operating in the negative mode. Products were analyzed in the multiple reaction monitoring (MRM) 
mode monitoring transitions from the parent ion to daughter ion of  179.1 (12 HETE [M-H]-) every 200 ms 
with a collision energy of  -45-42V. The AUC for the parent to 179.1 was integrated and normalized to the 
internal standard. For quantification of  these lipids, standard curves were generated with purified standards 
for each HETE-PE/PC.
Thrombin generation assays. Thrombin generation assays in plasma were performed using a Fluoroskan 
Ascent plate reader (ThermoLabsystems). Cleavage of  prothrombin to thrombin was measured using 0.5 
mmol/l fluorogenic substrate Z-Gly-Gly-Arg-AMC and thrombin activity compared with thrombin calibrator 
(Stago). Thrombin generation was calculated from raw fluorescence data (48). In some experiments, plasma 
congenitally deficient in FVIII, FIX, or FXI was used and/or anti-TFPI antibody was added at 80 nmol/l.
Activity of  individual coagulation complexes. The prothrombinase complex was assayed on the Fluo-
roskan Ascent plate reader using FII (1.4 μM), FXa (136 nM), and FVa (26 nM) in buffer B. Liposomes 
were made as above but without added TF. Since FXa directly cleaved the fluorogenic substrate (Z-Gly-
Gly-Arg-AMC) in the absence of  FIIa and PL, a FXa (136 nM) control was included. The change in 
fluorescence caused by FXa alone was subtracted from the fluorescence observed with FII, FXa, and FVa 
to give a measure of  FII cleavage to FIIa. The activity of  the TF/FVIIa complex was investigated with 
liposomes made in the presence of  50 pM full-length recombinant TF. FX (136 nM) and rFVIIa (10 nM) 
in buffer B was added, and conversion of  FX to FXa was measured on the Fluoroskan Ascent plate reader 
using the fluorogenic substrate (Z-Gly-Gly-Arg-AMC), which was not cleaved by rFVIIa/TF mixtures in 
the absence of  lipid. In place of  the thrombin calibrator, FXa (136 nM) was used. The intrinsic tenase 
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complex was investigated using liposomes without TF. FVIII was activated to FVIIIa (final concentration, 
300 pM) using thrombin (10 nM for 30 seconds), which was then inhibited by excess hirudin (50 nM). 
With the calcium and fluorogenic substrate (Z-Gly-Gly-Arg-AMC), the generated FVIIIa was immediate-
ly added to liposomes, FIXa (80 nM), and FX (136 nM), and the conversion of  FX to FXa was measured.
Coagulation enzyme complexes were also analyzed using kinetic approaches, in the presence of  4 μM 
liposomes with or without 12- or 15-HETE, with reactions being initiated using 5 mM CaCl2. The activ-
ity of  FIXa/FXa/FVIIa was measured in the presence of  variable substrate concentrations, obtaining an 
apparent Km for the enzyme-substrate complex and turnover number (Kcat).
Intrinsic tenase (FVIIIa/FIXa) activity was measured at 22°C in In buffer C (buffer A + 5mM CaCl2, 
0.1% Tween-20, 0.01% BSA) as previously described (9), using 1 nM FIXa and 10 nM FVIIIa using buffer 
B. FVIIIa was generated in situ as above. The reaction was stopped after 30 seconds, with a 4-fold volume 
excess of  5 mM EDTA in buffer A. 
Prothrombinase (FVa/FXa) activity was assayed at 37°C using 1 nM FXa/FVa and variable amounts 
of  prothrombin (0-2 μM) in buffer D (Buffer A + 5mM CaCL2, 0.01% BSA), stopping the reaction after 3 
minutes, with an equal volume of  25 mM EDTA in buffer A.
Extrinsic tenase (TF/FVIIa) complex activity was measured at 37°C using 10 pM recombinant TF 
(rTF) and 10 nM FVIIa in buffer D. The reaction was initiated by addition of  FX (0–0.5 μM) or FIX (0–2 
μM) in 5 mM CaCl2 and stopped after 5 minutes using an equal volume of  25 mM EDTA in buffer A (FX) 
or the same buffer using 75% ethylene glycol as solvent (FIX), at a final concentration of  30% ethylene 
glycol after addition of  substrate. Similar experiments were conducted using soluble TF (sTF) instead of  
full-length rTF.
The FXa, FIXa, and FIIa generated in these assays were measured by the amidolytic conversion of  
S-2765 (1 hour), CS-51 (3 hour), or Spectrozyme-TH (1 hour), respectively. A Biotek 96-well instrument 
was used to measure absorbance from cleaved substrates due to pNA (405 nM) release. Standard curves 
were constructed using known amounts of  FXa, FIXa, or FIIa, in order to determine the amount of  
enzyme activated by each of  the complexes. In the case of  FIXa, the standard curve was also done in the 
presence of  30% ethylene glycol.
Measurement of  liposome biophysical parameters. Liposomes were characterized for diameter, polydis-
persity index, conductivity, electrophoretic mobility, and charge (ζ potential) using a Zetasizer Nano 
ZS series ZEN3600 fitted with a 633 nm laser (Malvern Instruments Ltd.). Liposomes (50 μl) con-
taining 15-HETE-PE, generated as above, were added to 950 μl deionized water and placed in a clear 
plastic ζ cell (DTS 1070, Malvern) and equilibrated for 2 minutes at 25°C prior to measurement. Each 
was measured at least 4 times. Liposome diameter was also measured using by nanoparticle tracking 
analysis using a NanoSight LM10 system (Malvern Instruments Ltd.) running NTA-software v2.3 and 
configured with a temperature controlled, 488nm LM14 laser module and a high-sensitivity camera 
system (OrcaFlash2.8, Hamamatsu C11440). In brief, 4-mM liposomes were diluted 1,000 times in 
nano-particle free water (Fresenius Kabi) and analyzed under controlled fluid flow at 37°C, as pre-
viously described (49). Data were combined from 4 preparations done on different days, with each 
analyzed 5 times.
X-ray diffraction studies. Lipid mesophases were made up as follows in glass vials: 10% DOPS, 45% 
DOPC, 35%–45% SAPE, and 0%–10% 15-HETE-PE. Solvent was evaporated under N2 and then 
placed in a rapid-vac for 2 hours to remove residual solvent. Dried lipid film was scraped off  using a 
pipette tip. Water was added to give 60% (wt/wt) hydration. Lipid mixtures were centrifuged to the bot-
tom of  the vial and then stirred again using a pipette tip. Samples were then heat-cycled 10 times. For 
this, liquid N2 was used to freeze the lipid mixture, followed by thawing at room temperature. SAXS 
experiments were carried out at beamline I22 (Diamond Light Source). The samples were contained in 
thin-walled glass capillary tubes and held at 37°C ± 0.1°C. The beamline was configured to deliver 12 
keV X-rays, and images were captured using a Dectris Pilatus 2M detector at 2.25 m from the sample 
position. Diffraction images were integrated using a custom software package developed using the IDL 
programming language and calibrated against silver behenate, which has a well-defined layer spacing 
of  58.38 Å (50).
Nanodisc preparation and surface plasmon resonance (SPR). Nanodiscs of  varying lipid compositions 
were prepared as described with the following modifications (51). Lipids were mixed in buffer containing 
56.3 mM deoxycholate at 43°C so as to facilitate solubility. All steps up to the addition of  Bio-beads 
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were performed at 43°C. Prothrombin and FX binding to nanodiscs was evaluated using a Biacore 3000 
instrument as described (37). Binding isotherms were plotted using the maximal steady-state binding 
response units (RU) vs. concentration of  protein flowed over the chip, from which Kd and maximal pro-
tein-binding RU (RUmax) values were derived using the single-site ligand binding equation. Molecules of  
protein bound per leaflet were determined using the following equation:
([RUmax/RUdisc] × [MWdisc/MWprotein])/2,
where RUdisc equals the RU change from disc loading, MWdisc equals the molecular weight of  the Nanodisc, 
and MWprotein equals the protein molecular weight.
Statistics. Statistics were analyzed using 1-way ANOVA. Post hoc Tukey tests were used to determine 
P values between individual data groups. The Mann Whitney U test was applied to examine differenc-
es between unrelated variables, while the Wilcoxon Rank test was used to examine differences between 
related samples. Analysis of  multiple related samples was performed using Friedman’s test. P < 0.05 was 
considered significant.
Study approval. All blood donations were approved by the Cardiff  University School of  Medicine Eth-
ics Committee, were with informed consent (SMREC 12/37, SMREC 12/10), and were in accordance 
with the Declaration of  Helsinki. Patients undergoing heart valve surgery with or without coronary artery 
bypass grafting and procedures on the aorta were recruited under a protocol approved by the South West 
Wales Research Ethics Committee (reference 11/WA/0215). Tail-bleeding assays in mice were performed 
under United Kingdom Home Office License PPL/3150.
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